Scott Lish Sells 27,453 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 27,453 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the completion of the transaction, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. This trade represents a 3.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Alphatec Price Performance

ATEC stock traded down $0.06 during mid-day trading on Friday, reaching $11.36. 998,281 shares of the company’s stock were exchanged, compared to its average volume of 1,776,835. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $17.34. The stock’s 50 day moving average is $10.26 and its 200 day moving average is $8.13. The company has a market cap of $1.61 billion, a price-to-earnings ratio of -8.88 and a beta of 1.43.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ATEC. State Street Corp increased its holdings in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock worth $17,453,000 after acquiring an additional 287,350 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in shares of Alphatec by 11.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,928,094 shares of the medical technology company’s stock valued at $16,280,000 after purchasing an additional 297,850 shares during the period. Royce & Associates LP increased its stake in shares of Alphatec by 15.9% during the third quarter. Royce & Associates LP now owns 1,212,286 shares of the medical technology company’s stock worth $6,740,000 after purchasing an additional 165,954 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Alphatec by 21.2% during the 4th quarter. New York State Common Retirement Fund now owns 1,202,334 shares of the medical technology company’s stock worth $11,037,000 after purchasing an additional 210,519 shares during the last quarter. Finally, Walleye Capital LLC lifted its stake in Alphatec by 3.2% in the 3rd quarter. Walleye Capital LLC now owns 1,061,462 shares of the medical technology company’s stock valued at $5,902,000 after buying an additional 32,529 shares in the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analysts Set New Price Targets

ATEC has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a research note on Tuesday, January 14th. Needham & Company LLC lifted their price target on Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Barclays upped their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.56.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.